Format

Send to

Choose Destination
Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x. Epub 2012 Jul 30.

Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.

Author information

1
Department of Emergency and Admission, Critical Care Medicine, Pain Medicine and Anaesthetic Science. Foundation PTV Polyclinic Tor Vergata. University of Rome Tor Vergata, Rome, Italy. antonio.gatti@ptvonline.it

Abstract

OBJECTIVE:

To assess the efficacy and safety of palmitoylethanolamide (PEA), an endogenous fatty acid amide belonging to the N-acylethanolamines family, in reducing pain severity in patients with pain associated to different pathological conditions.

METHODS:

This was an observational study conducted on 610 patients who were unable to effectively control chronic pain with standard therapies. PEA (600 mg) was administered twice daily for 3 weeks followed by single daily dosing for 4 weeks, in addition to standard analgesic therapies or as single therapy. The primary outcome measure was the mean score pain severity evaluated by the numeric rating scale. Safety was also evaluated.

RESULTS:

PEA treatment significantly decreased the mean score pain intensity evaluated in all patients who completed the study. The PEA effect was independent of the pain associated pathological condition. PEA-induced decrease of pain intensity was present also in patients without concomitant analgesic therapy. Importantly, PEA showed no adverse effects.

CONCLUSIONS:

In this study, PEA was effective and safe in the management of chronic pain in different pathological conditions.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center